title: Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells.
abstract: BACKGROUND
  Our group has previously shown that EPHRIN-A1 and SCINDERIN expression by tumor cells rendered them resistant to cytotoxic T lymphocyte-mediated lysis. Whereas the prognostic value of EPHRIN-A1 expression in cancer has already been studied, the role of SCINDERIN presence remains to be established. In the present work, we investigated the prognosis value of EPHRIN-A1 and SCINDERIN expression in head and neck carcinomas. In addition, we monitored the HLA-class I expression by tumor cells and the presence of tumor-infiltrating CD8+ T cells to evaluate a putative correlation between these factors and the survival prognosis by themselves or related to EPHRIN-A1 and SCINDERIN expression.
  
  
  METHODS
  Tumor tissue sections of 83 patients with head and neck cancer were assessed by immunohistochemistry for the expression of EPHRIN-A1, SCINDERIN, HLA class I molecules and the presence of CD8+ T cells.
  
  
  RESULTS
  No significant prognosis value could be attributed to these factors independently, despite a tendency of association between EPHRIN-A1 and a worse clinical outcome. No prognostic value could be observed when CD8+ T cell tumor infiltration was analyzed combined with EPHRIN-A1, SCINDERIN or HLA class I expression.
  
  
  CONCLUSIONS
  These results highlight that molecules involved in cancer cell resistance to cytotoxic T lymphocytes by themselves are not a sufficient criteria for prognosis determination in cancer patients. Other intrinsic or tumor microenvironmental features should be considered in prognostic evaluation.
authors: Meriem
authors: M
authors: Hasmim
authors: Cécile
authors: C
authors: Badoual
authors: Philippe
authors: P
authors: Vielh
authors: Françoise
authors: F
authors: Drusch
authors: Virginie
authors: V
authors: Marty
authors: Agnès
authors: A
authors: Laplanche
authors: Mariana
authors: M
authors: de Oliveira Diniz
authors: Hélène
authors: H
authors: Roussel
authors: Eléonore
authors: E
authors: De Guillebon
authors: Stéphane
authors: S
authors: Oudard
authors: Stéphane
authors: S
authors: Hans
authors: Eric
authors: E
authors: Tartour
authors: U753-INSERM, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94800 Villejuif, France. chouaib@igr.fr.
authors: Salem
authors: S
authors: Chouaib
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D036382:Ephrin-A1 / Q000378:metabolism*; D005260:Female; D018260:Gelsolin / Q000378:metabolism*; D006258:Head and Neck Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D015395:Histocompatibility Antigens Class I / Q000378:metabolism*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; D036382:Ephrin-A1; D018260:Gelsolin; D015395:Histocompatibility Antigens Class I; C065395:scinderin